NCT04345913 2026-04-13Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerNational Cancer Institute (NCI)Phase 1/2 Active not recruiting24 enrolled 24 charts
NCT05104866 2026-02-04A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)AstraZenecaPhase 3 Active not recruiting732 enrolled 22 charts 3 FDA